Keywords: USA, FDA advisory panel recommendations, Onyx Pharma, Kyprolis, Carfilzomib, Sanofi, Semuloparin, Pfizer, Prevnar 13, Merck & Co, Pneumovax 23
Batch of mixed opinions from FDA advisory panels
Article | 21 June 2012
Advisory panels of the US Food and Drug Administration meeting yesterday came back with a mixture of views on approval ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- New study shows UCB's Neupro reduces NSBP in RLS patient
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
